摘要
目的探讨一线使用盐酸安罗替尼联合化疗后序贯盐酸安罗替尼治疗广泛期小细胞肺癌的治疗效果及安全性。方法选取2020年1月1日-2021年12月31日在咸阳市中心医院确诊的广泛期小细胞肺癌患者128例,按照随机数字表法分为对照组和试验组,各64例。对照组采用单纯EP方案化疗,试验组行盐酸安罗替尼联合EP方案化疗,比较两组生存期及安全性。结果对照组中位无进展生存期(PFS)少于试验组,差异有统计学意义(P<0.05);对照组中位总生存期(OS)少于试验组,差异有统计学意义(P<0.05);两组不良反应均为Ⅰ~Ⅱ级不良反应,试验组血小板减少、手足综合征、口腔溃疡、牙龈出血、高血压的发生比例高于对照组。结论盐酸安罗替尼一线联合化疗能够改善广泛期小细胞肺癌患者生存期且安全性较高。
Objective To investigate the efficacy and safety of first-line anlotinib hydrochloride combined with chemotherapy followed by sequential anlotinib hydrochloride in the treatment of extensive stage small cell lung cancer.Methods A total of 128 patients with extensive small cell lung cancer diagnosed in Xianyang Central Hospital from January 1,2020 to December 31,2021 were selected and divided into control group and experimental group according to the random number table method,with 64 cases in each group.The control group was treated with EP regimen alone,and the experimental group was treated with anlotinib hydrochloride combined with EP regimen.The survival time and safety of the two groups were compared.Results The median progression-free survival(PFS)of the control group was less than that of the experimental group,and the difference was statistically significant(P<0.05).The median overall survival(OS)of the control group was less than that of the experimental group,and the difference was statistically significant(P<0.05).The adverse reactions of the two groups were gradeⅠ-Ⅱadverse reactions.The incidence of thrombocytopenia,hand-foot syndrome,oral ulcer,gingival bleeding and hypertension in the experimental group was higher than that in the control group.Conclusion Anlotinib hydrochloride combined with first-line chemotherapy can significantly improve the survival time and safety of patients with extensive small cell lung cancer.
作者
何小鹏
高亭
HE Xiao-peng;GAO Ting(Department of Respiratory Medicine,Xianyang Central Hospital,Xianyang 712000,Shaanxi,China)
出处
《医学信息》
2022年第23期76-79,共4页
Journal of Medical Information
基金
北京康盟慈善基金会医学科研发展基金项目(编号:TB212029)
陕西中医药大学校级课题(编号:2021FS06)。
关键词
小细胞肺癌
盐酸安罗替尼
生存期
Small cell lung cancer
Anlotinib hydrochloride
Chemotherapy
Survival time
